Profound Medical Corp
Change company Symbol lookup
Select an option...
PROF Profound Medical Corp
ELGXQ Endologix Inc
ONOV BioNovelus Inc
ATO Atmos Energy Corp
NMS Nuveen Minnesota Quality Municipal Income Fund
INVVY Indivior PLC
OSUR OraSure Technologies Inc
QUOT Quotient Technology Inc
DUK Duke Energy Corp
WAFD Washington Federal Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Based in Canada
Company profile

Profound Medical Corp. is a commercial-stage medical device company. focused on customizable, incision-free therapies which combine real-time magnetic resonance imaging (MRI), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. The Company’s products include TULSA-PRO System and SONALLEVE. The TULSA-PRO is used to ablate benign or malignant prostate tissue in patients with a variety of prostate diseases. Prostate diseases include prostate cancer and benign prostatic hyperlasia (BPH). Prostate cancer is one of the common types of cancer affecting men. TULSA-PRO and SONALLEVE share the common technological concept of using MRI to enable visualization of the surgeon desired tissue in real time. Both products also use thermal ultrasound technology to heat and ablate tissue.

Price
Delayed
$16.67
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 0 shares is on pace to be much lighter than PROF's 10-day average volume of 137,048 shares.

0

Nvidia stock gains after Needham boosts target to new Street high of $700

9:09 am ET September 15, 2020 (MarketWatch)
Print

Shares of Nvidia Corp. (NVDA) are up more than 3% in premarket trading Tuesday after Needham analyst Rajvindra Gill upped his price target on the stock to $700 from $600. His new target is the highest listed on FactSet. Gill is increasingly upbeat on Nvidia's prospects after the company announced over the weekend that it would be acquiring Arm from Softbank Group Corp. in a deal valued at $40 billion. "Strategically, we believe the Nvidia-Arm combination will create the leading AI computing platform in the semiconductor industry," Gill wrote in his note to clients. "The combination of three processors under one house - GPUs for accelerated computing, NPUs for networking and security processing, and CPUs for low latency, single thread predictable processing - positions NVDA to become the leading AI platform in the industry, in our view." He argued that a "multi-processor and multi-architecture framework will be paramount" in dealing with the next generation of artificial-intelligence workloads. Nvidia shares have gained 40% over the past three months as the S&P 500 has risen 10%.

-Emily Bary; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 15, 2020 09:09 ET (13:09 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.